DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PAR DRUGS AND CHEM LTD (PAR) share price today?

PAR DRUGS AND CHEM LTD (PAR) is trading at ₹104.93 on the NSE, up 10.42% on the day. Source: DocStoX.

What is the PE ratio of PAR DRUGS AND CHEM LTD?

PAR DRUGS AND CHEM LTD has a price-to-earnings (PE) ratio of 9.7 in the Healthcare sector.

What is the market capitalisation of PAR DRUGS AND CHEM LTD?

PAR DRUGS AND CHEM LTD has a market capitalisation of approximately ₹112 crore.

PAR DRUGS AND CHEM LTD

PAR·NSE·Healthcare

₹104.93▲ +9.90 (+10.42%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹95.60

₹111.70

52W₹78

₹12261%

Open

₹98.00

High

₹111.70

Low

₹95.60

Prev Close

₹95.03

Volume

3.42L

VWAP

₹106.73

Snapshot

Key fundamentals

Market Cap

₹112 Cr

P/E Ratio

9.66Cheap

P/B Ratio

0.98

EPS

₹10.86

Book Value

₹91.01

ROE

12.43%Average

ROCE

18.00%Decent

Dividend Yield

1.39%

Debt / Equity

0.00Low

Face Value

₹10.00

52W High

₹122.43

52W Low

₹78.05

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

Narrow moatHigh uncertainty

Fair value estimate

₹110

▲ 4.5%upside

Trading at ₹105 — 5% below our estimate

BearFair valueBull

₹93₹110₹148

/100

Business quality — Solid

Growth 17Profitability 49Efficiency 25Valuation 100

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 1/9)

Strengths

Virtually debt-free balance sheet
Reasonably priced at 10× earnings
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

14% ROE fading to 12% over ~10 yrs, on ₹91 book

₹99

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹148

Analyst target

No analyst coverage

—

Blended fair value₹110

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Reasonably priced at 10× earnings
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

9.7Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

12.4%Average

Above 15% is considered healthy for Indian equities

ROCE

18.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹112 Cr

P/B

0.98

EPS

₹10.86

Div Yield

1.39%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 9.7×

Growth

Slow

+3% rev CAGR

Profitability

Healthy

12.4% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %21.0%

Turnover₹364.91L Cr

Trades4,732

VWAP₹106.73

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+2.6%

+11.2%

10Y

+12.1%

Profit

+5.1%

+1.3%

10Y

—

EPS

+5.0%

+2.4%

10Y

+29.9%

Profile

Pros

Company is almost debt free.
Stock is trading at 0.98 times its book value

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of 11.3% over past five years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

73%

Promoter

Promoters

73.4%0.00

Public

20.0%-0.06

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

6.6%

Total shareholders

13,222-539 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter73.41%

Public19.97%

Others6.62%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals[1]